The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...

Medically reviewed by Marla Anderson, MD Key Takeaways Triple-negative breast cancer is aggressive and often resists ...

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage ...

Eligible patients had received between one and four previous lines of chemotherapy. Credit: Thomas Andreas via Shutterstock. AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway ...

Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks estrogen, progesterone, and HER2 receptors ...

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

We conducted a retrospective cohort study of patients with TNBC treated between 2010 and 2019. Overall survival (OS) rates by stage were analyzed across various patient groups, including those ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug to outperform chemotherapy in immunotherapy-ineligible metastatic ...